Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Repurposing flavopiridol as an inhaled therapeutic for pulmonary fibrosis

European Journal of Pharmacology(2025)10.1016/j.ejphar.2025.178058Source: DataRank Database

Repurposing flavopiridol as an inhaled therapeutic for pulmonary fibrosis is a research paper published in European Journal of Pharmacology (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

geo

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 0.00)OA: hybridTopics (53)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (10)

Subash K. Chaudhary,Wen‐Hsin Chang ORCID,David C.H. Yang ORCID,So-Yi Chang,Jihao Xu ORCID

Live enrichment

PubMed:40816528 PMC:PMC12479379 OpenAlex:https://openalex.org/W4413160437

National Heart, Lung, and Blood Institute

Grant: R01HL177797

National Heart, Lung, and Blood Institute

Grant: R01HL146802

U.S. Department of Defense

Grant: PR200947

U.S. Department of Defense

Grant: PR202411

Tobacco-Related Disease Research Program

Grant: T32IR5347

National Institutes of Health

FWCI

0.00

Citation Percentile

0.2%

hybridLicense: cc-by-nc-nd

journalhttps://doi.org/10.1016/j.ejphar.2025.178058

publisherhttps://doi.org/10.1016/j.ejphar.2025.178058

publisherhttps://api.elsevier.com/content/article/PII:S001429992500812X?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S001429992500812X?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40816528

Fields of Study

Interstitial Lung Diseases and Idiopathic Pulmonary FibrosisInhalation and Respiratory Drug DeliveryNeonatal Respiratory Health ResearchAnimalsPiperidinesFlavonoidsMiceHumansIdiopathic Pulmonary FibrosisCyclin-Dependent Kinase 9Drug RepositioningAdministration, InhalationMaleFibroblastsLungDisease Models, AnimalCell ProliferationMice, Inbred C57BLIndolesBleomycinProtein Kinase Inhibitors

MeSH Terms

Administration, InhalationAnimalsBleomycinDisease Models, AnimalFibroblastsFlavonoidsHumansIndolesLungMaleMice, Inbred C57BLPiperidinesCyclin-Dependent Kinase 9Protein Kinase InhibitorsCell ProliferationMiceIdiopathic Pulmonary FibrosisDrug Repositioning

Keywords

RepurposingPulmonary fibrosisMedicineDrug repositioningPharmacologyFibrosisInternal medicineBiologyDrugFibroblastsLung fibrosisCDK9FlavopiridolInhaled Drugs

Sustainable Development Goals

SDG 0: Zero hunger

Repurposing flavopiridol as an inhaled therapeutic for pulmonary fibrosis

FAIR Checklist

Authors (10)

Funding (6 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)